117 related articles for article (PubMed ID: 12699722)
1. A quantitative illustration of the public health potential of aspirin.
Morgan G
Med Hypotheses; 2003 Jun; 60(6):900-2. PubMed ID: 12699722
[TBL] [Abstract][Full Text] [Related]
2. A long-term risk-benefit analysis of low-dose aspirin in primary prevention.
Wu IC; Hsieh HM; Yu FJ; Wu MC; Wu TS; Wu MT
Eur J Clin Invest; 2016 Feb; 46(2):130-40. PubMed ID: 26640116
[TBL] [Abstract][Full Text] [Related]
3. Does low-dose aspirin use for cardiovascular disease prevention reduce colorectal cancer deaths? A comparison of two cohorts in the Florence district, Italy.
Ventura L; Miccinesi G; Barchielli A; Manneschi G; Puliti D; Mantellini P; Orso F; Zappa M
Eur J Cancer Prev; 2018 Mar; 27(2):134-139. PubMed ID: 27845951
[TBL] [Abstract][Full Text] [Related]
4. Benefit-harm analysis and charts for individualized and preference-sensitive prevention: example of low dose aspirin for primary prevention of cardiovascular disease and cancer.
Puhan MA; Yu T; Stegeman I; Varadhan R; Singh S; Boyd CM
BMC Med; 2015 Oct; 13():250. PubMed ID: 26423305
[TBL] [Abstract][Full Text] [Related]
5. Which Aspirin Dose and Preparation Is Best for the Long-Term Prevention of Cardiovascular Disease and Cancer? Evidence From a Systematic Review and Network Meta-Analysis.
Lotrionte M; Biasucci LM; Peruzzi M; Frati G; Giordano A; Biondi-Zoccai G
Prog Cardiovasc Dis; 2016; 58(5):495-504. PubMed ID: 26851562
[TBL] [Abstract][Full Text] [Related]
6. Aspirin for Primary Prevention of Cardiovascular Disease and Cancer. A Benefit and Harm Analysis.
Stegeman I; Bossuyt PM; Yu T; Boyd C; Puhan MA
PLoS One; 2015; 10(7):e0127194. PubMed ID: 26151751
[TBL] [Abstract][Full Text] [Related]
7. On the unfulfilled public health potential of aspirin.
Morgan GP
Eur J Public Health; 2010 Aug; 20(4):374-5. PubMed ID: 20660179
[No Abstract] [Full Text] [Related]
8. Aspirin therapy and primary prevention of cardiovascular disease in diabetes mellitus.
Younis N; Williams S; Soran H
Diabetes Obes Metab; 2009 Nov; 11(11):997-1000. PubMed ID: 19531055
[TBL] [Abstract][Full Text] [Related]
9. Issues in the early termination of the aspirin component of the Physicians' Health Study. Data Monitoring Board of the Physicians' Health Study.
Cairns J; Cohen L; Colton T; DeMets DL; Deykin D; Friedman L; Greenwald P; Hutchison GB; Rosner B
Ann Epidemiol; 1991 Aug; 1(5):395-405. PubMed ID: 1669520
[TBL] [Abstract][Full Text] [Related]
10. Ethical considerations in relation to aspirin prophylaxis.
Morgan G
Qual Prim Care; 2008; 16(6):433-40. PubMed ID: 19094419
[TBL] [Abstract][Full Text] [Related]
11. Women's study finds vitamin E, aspirin not so helpful.
Harv Womens Health Watch; 2005 Sep; 13(1):6. PubMed ID: 16224840
[No Abstract] [Full Text] [Related]
12. Age threshold for vascular prophylaxis by aspirin in patients without diabetes.
Bulugahapitiya U; Siyambalapitiya S; Sithole J; Fernando DJ; Idris I
Heart; 2008 Nov; 94(11):1429-32. PubMed ID: 18708419
[TBL] [Abstract][Full Text] [Related]
13. Effect of baseline gastrointestinal risk and use of proton pump inhibitors on frequency of discontinuation of aspirin for secondary cardiovascular prevention in United kingdom primary care.
Martín Merino E; Johansson S; Nagy P; García Rodríguez LA
Am J Cardiol; 2013 Oct; 112(8):1075-82. PubMed ID: 23831164
[TBL] [Abstract][Full Text] [Related]
14. Aspirin in the prevention of cancer.
Wald NJ; Morris JK; Law MR
Lancet; 2011 May; 377(9778):1649; author reply 1651-2. PubMed ID: 21571138
[No Abstract] [Full Text] [Related]
15. Incidence of colorectal cancer in new users and non-users of low-dose aspirin without existing cardiovascular disease: A cohort study using The Health Improvement Network.
Cea Soriano L; Soriano-Gabarró M; García Rodríguez LA
Int J Cardiol; 2017 Dec; 248():376-381. PubMed ID: 28942878
[TBL] [Abstract][Full Text] [Related]
16. Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy women.
van Kruijsdijk RC; Visseren FL; Ridker PM; Dorresteijn JA; Buring JE; van der Graaf Y; Cook NR
Heart; 2015 Mar; 101(5):369-76. PubMed ID: 25475110
[TBL] [Abstract][Full Text] [Related]
17. A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan.
Tsutani K; Igarashi A; Fujikawa K; Evers T; Kubin M; Lamotte M; Annemans L
Intern Med; 2007; 46(4):157-62. PubMed ID: 17301509
[TBL] [Abstract][Full Text] [Related]
18. Killing two birds with one salicylate: aspirin's dual roles in preventative health.
Antonoff MB; D'Cunha J
Semin Thorac Cardiovasc Surg; 2011; 23(2):96-8. PubMed ID: 22041037
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.
Chen J; Bhatt DL; Dunn ES; Shi C; Caro JJ; Mahoney EM; Gabriel S; Jackson JD; Topol EJ; Cohen DJ
Value Health; 2009 Sep; 12(6):872-9. PubMed ID: 19490556
[TBL] [Abstract][Full Text] [Related]
20. Aspirin: promise and resistance in the new millennium.
Patrono C; Rocca B
Arterioscler Thromb Vasc Biol; 2008 Mar; 28(3):s25-32. PubMed ID: 18174450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
